GSK's Jemperli Trial Meets Ovarian Cancer Endpoint
Ticker: GLAXF · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, oncology, drug-development
Related Tickers: GSK
TL;DR
GSK's Jemperli trial successful in first-line advanced ovarian cancer, boosting treatment options.
AI Summary
GSK plc announced on December 20, 2024, that its Phase III FIRST trial met its primary endpoint for progression-free survival in first-line advanced ovarian cancer. The trial investigated the addition of Jemperli (dostarlimab) to platinum-based chemotherapy.
Why It Matters
This positive trial result could lead to an expanded use of Jemperli, potentially offering a new treatment option for patients with advanced ovarian cancer.
Risk Assessment
Risk Level: low — The filing is an informational report on a clinical trial outcome, not a financial transaction or regulatory action that typically carries higher risk.
Key Players & Entities
- GSK plc (company) — Registrant and subject of the announcement
- Jemperli (dostarlimab) (company) — Drug investigated in the trial
- 20 December 2024 (date) — Date of the announcement
FAQ
What was the primary endpoint of the Phase III FIRST trial?
The primary endpoint was progression-free survival in first-line advanced ovarian cancer.
What drug was being investigated in the FIRST trial?
The drug investigated was Jemperli (dostarlimab).
When was this announcement made by GSK plc?
The announcement was issued on 20 December 2024.
What type of cancer was the trial focused on?
The trial was focused on first-line advanced ovarian cancer.
What was Jemperli added to in the trial regimen?
Jemperli was added to platinum-based chemotherapy.
Filing Stats: 1,730 words · 7 min read · ~6 pages · Grade level 14.6 · Accepted 2024-12-20 10:26:21
Filing Documents
- a8451q.htm (6-K) — 55KB
- 0001654954-24-015791.txt ( ) — 56KB
SIGNATURES
SIGNATURES     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: December 20, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc